Topic: International Drug Pricing
-
Dissecting PhRMA’s Opposition to H.R. 3 Lower Drug Costs Now Act of 2019
Read More
-
US Drug Prices And R&D, Take 2: A Reply To Grabowski And Manning, And To Light
Read More
-
DPL responds to HHS Blueprint (May 16, 2018)
Read More
-
R&D Costs Do Not Explain Elevated U.S. Drug Prices
Read More